While these results appear promising and suggest non-immune mediated effects of PD-1-based treatments, as this study was not performed in an immunocompetent model, a deficiency remains in our understanding of how these therapies act in concert to promote anti-tumor immunity. Here, PDCD1 is linked to neoplasm.